Colucci Norman
Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Thursday, October 23, 2008

NitroMed to sell its only revenue source, BiDil, for $24.5M

By Mass High Tech Staff

Targeted drug maker NitroMed Inc. plans to sell its BiDil drug business to JHP Pharmaceuticals LLC for a possible $26.3 million. New Jersey-based JHP, a privately held specialty pharmaceutical company, will buy the assets related to BiDil for $24.5 million in cash, plus up to an additional $1.8 million for inventory at the closing date.

JHP will also assume all but some specified liabilities related to the assets it is acquiring, according to officials. The companies say they expect to complete the sale in early 2009.

According to NitroMed (Nasdaq: NTMD) officials, the deal has the backing of a number of its investors, from firms including HealthCare Ventures LLC, Rho Ventures and Invus Public Equities LP.

In January, Lexington-based NitroMed laid off most of its staff and suspended marketing efforts for BiDil, a heart failure pill designed specifically for African-American patients. BiDil is approved in the United States as an adjunct to current standard therapies. At that time the company said it planned to study an extended release implementation of BiDil.

The company at that time also hired investment banking firm Cowen and Co. LLC for advice on the firm’s strategic options.

NitroMed also reported its financial results for the third quarter which ended Sept. 30. The company’s total revenues climbed slightly to $4 million, compared to $3.8 million for the same period in 2007. All of that revenue came from sales of BiDil, officials said. NitroMed’s net loss dropped to $400,000 for the quarter, compared to a net loss of $8.4 million last year.
 

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Healy Jones: Avoid jerks, dolts when looking for VCs

At his Startable blog, Healy Jones lists VC qualities best avoided, including micromanagement and bad breath. Healy suggests performing reverse due diligence: You’ll want to have an honest, founder-a-founder conversation. Your goal is to make sure that they venture capitalist is someone who you want intimately involved with your company for the next five+ years. Are they trustworthy, do they a...

Read More

Most Popular Stories
EmailedViewed
Goulston Storrs
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio